查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971924

放射性药物市场分析及预测（至2035年）：依类型、产品、应用、最终使用者、技术、剂型、服务、模式及阶段划分

Radiopharmaceuticals Market Analysis and Forecast to 2035: Type, Product, Application, End User, Technology, Form, Services, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 325 Pages | 商品交期: 3-5个工作天内

价格
简介目录

放射性药物市场预计将从2024年的184亿美元成长到2034年的720亿美元，复合年增长率约为14.6%。放射性药物市场包括用于核子医学诊断和治疗的化合物，这些化合物将放射性同位素与药物成分结合。这些药物针对特定器官、组织或细胞受体，从而实现对癌症等疾病的精准成像和治疗。推动该市场成长的因素包括医学影像技术的进步、慢性病盛行率的上升以及放射性标记技术的创新，这些因素共同促进了诊断和治疗应用的发展。

放射性药物市场持续强劲成长，这主要得益于核医学的进步和对标靶治疗日益增长的需求。在诊断领域，PET示踪剂作为肿瘤学和神经病学应用的关键工具，发挥主导作用。 SPECT示踪剂紧随其后，反映出其在心臟病学和骨骼影像领域的重要性。在治疗领域，放射性标记的单株抗体因其能够特异性靶向癌细胞而备受关注。胜肽受体放射性核种疗法（PRRT）也正在成为治疗方法神经内分泌肿瘤的一种有前景的方法。市场正朝着治疗诊断学发展，将诊断影像和治疗功能结合，从而强化个人化医疗模式。新型放射性同位素的开发和放射化学的进步进一步加速了市场成长。製药公司与研究机构之间的策略合作正在促进创新并加速临床试验。预计对放射性药物研发投入的增加以及监管支持的加强将继续保持市场成长动能。

市场区隔
类型 诊断用放射性药物，治疗放射性药物
产品 Technetium-99m、碘-131、氟脱氧葡萄糖 (FDG)、镓-68、镏-177、钇-90、镭-223、钐-153、锶-89
目的 肿瘤科、心臟科、神经科、内分泌科、消化科、肾臟科、整形外科
最终用户 医院、诊断中心、门诊手术中心、学术研究机构、製药公司及生技公司
科技 迴旋加速器、核子反应炉、线性加速器
形式 液体、固体、气体
服务 放射性同位素的生产、放射性药物的生产、品管和测试、法规遵循、物流和配送。
模式 内部、外包
步 临床前、临床、商业化

市场概况：

放射性药物市场呈现市场份额分布动态变化、定价策略竞争激烈以及新产品上市数量激增的特征。主要企业正致力于创新技术以强化产品系列。市场正经历着向精准医疗的转型，推动了对标靶放射性药物疗法的需求。北美地区凭藉其在研发领域的巨额投资，依然保持着市场主导地位。欧洲和亚太地区也正经历显着成长，这主要得益于医疗费用支出的成长和技术的进步。对竞争格局的基准研究表明，策略联盟和併购是市场的重要组成部分。各公司正利用伙伴关係来扩大其全球影响力并强化其产品线。监管影响至关重要，严格的监管准则对市场准入和合规性有重大影响。美国食品药物管理局（FDA）和欧洲药品管理局（EMA）是塑造市场动态的关键监管机构。随着市场的不断发展，对安全性和有效性的关注持续推动创新，并为相关人员提供了盈利的机会。

主要趋势和驱动因素：

放射性药物市场正经历强劲成长，这主要得益于核医和个人化医疗的进步。关键趋势包括放射性药物在癌症诊断和治疗中的应用日益广泛，精准医疗的重要性也日益凸显。针对特定癌症类型的新型放射性药物的研发，有助于提高治疗效果和改善患者预后。此外，慢性病的日益增加和人口老化也推动了对诊断影像检查的需求。混合成像系统等技术创新进一步加速了市场扩张。监管支持和优惠的报销政策鼓励对放射性药物研发进行投资。製药公司与研究机构之间的策略合作在市场中也占据重要地位，促进了创新。新兴市场医疗基础设施的不断完善也带来了许多机会。专注于拓展产品系列和地理覆盖范围的公司将能够更好地掌握这些趋势。在持续的科学技术进步和不断增长的医疗保健需求的推动下，放射性药物市场预计将保持持续成长。

抑制因素和挑战：

放射性药物市场面临许多重大限制与挑战。其中一项主要挑战是严格的监管环境。监管机构严格的测试和核准流程导致新产品上市延迟，阻碍了中小企业进入市场，并抑制了创新。另一项挑战是放射性药物生产高成本。对专用设施和设备的需求增加了营运成本，限制了市场扩张。此外，由于许多放射性药物的半衰期较短，透过可靠的供应链及时交付至关重要，这进一步增加了物流的复杂性。市场也面临熟练专业人员短缺的问题。核子医学专业知识对于放射性药物的安全操作和应用至关重要，但合格人员数量有限。此外，公众对辐射的认知和担忧也构成障碍。对安全性的误解导致人们对放射性药物疗法犹豫不决，从而影响了市场成长。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制因素
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章：细分市场分析

  • 市场规模及预测：依类型
    • 诊断用放射性药物
    • 用于治疗的放射性药物
  • 市场规模及预测：依产品划分
    • Technetium-99m
    • 碘-131
    • 氟代脱氧葡萄糖（FDG）
    • 镓-68
    • 镏-177
    • 钇90
    • 镭-223
    • 钐153
    • 锶-89
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 心臟病学
    • 神经病学
    • 内分泌学
    • 胃肠病学
    • 肾臟病学
    • 整形外科
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊断中心
    • 门诊手术中心
    • 学术研究机构
    • 製药公司和生技公司
  • 市场规模及预测：依技术划分
    • 迴旋加速器
    • 核子反应炉
    • 线性加速器
  • 市场规模及预测：依类型
    • 液体
    • 固体的
    • 气体
  • 市场规模及预测：依服务划分
    • 放射性同位素的生产
    • 放射性药物的生产
    • 品管和测试
    • 监理合规
    • 物流/配送
  • 市场规模及预测：按模式
    • 内部
    • 外包
  • 市场规模及预测：依阶段划分
    • 临床前
    • 临床
    • 商业化

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 供需差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 监管概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Advanced Accelerator Applications
  • Blue Earth Diagnostics
  • ITM Isotope Technologies Munich
  • Lantheus Medical Imaging
  • Jubilant Radiopharma
  • Curium
  • Telix Pharmaceuticals
  • Bayer Radiopharma
  • NorthStar Medical Radioisotopes
  • Eckert & Ziegler
  • Sofie Biosciences
  • Cardinal Health Radiopharmacy
  • Isotopia Molecular Imaging
  • Radiomedix
  • ImaginAb

第九章 关于我们

简介目录
Product Code: GIS34195

Radiopharmaceuticals Market is anticipated to expand from $18.4 billion in 2024 to $72 billion by 2034, growing at a CAGR of approximately 14.6%. The Radiopharmaceuticals Market encompasses compounds used in nuclear medicine for diagnosis and therapy, integrating radioactive isotopes with pharmaceutical agents. These agents target specific organs, tissues, or cellular receptors, enabling precise imaging and treatment of diseases like cancer. The market is driven by advancements in medical imaging, increasing prevalence of chronic diseases, and innovations in radiolabeling techniques, fostering growth in diagnostic and therapeutic applications.

The Radiopharmaceuticals Market is experiencing robust expansion, fueled by advancements in nuclear medicine and increasing demand for targeted therapies. The diagnostic segment leads in performance, particularly with the dominance of PET tracers, which are essential in oncology and neurology applications. SPECT tracers follow, reflecting their continued relevance in cardiology and bone imaging. In the therapeutic segment, radiolabeled monoclonal antibodies are gaining momentum, driven by their specificity in targeting cancer cells. Peptide receptor radionuclide therapy (PRRT) is also emerging as a promising treatment for neuroendocrine tumors. The market is witnessing a shift towards theranostics, combining diagnostic imaging and therapeutic capabilities, enhancing personalized medicine approaches. The development of novel radioisotopes and advancements in radiochemistry are further propelling market growth. Strategic partnerships and collaborations among pharmaceutical companies and research institutions are fostering innovation and accelerating clinical trials. Increasing investments in R&D and regulatory support for radiopharmaceuticals are expected to sustain market momentum.

Market Segmentation
TypeDiagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals
ProductTechnetium-99m, Iodine-131, Fluorodeoxyglucose (FDG), Gallium-68, Lutetium-177, Yttrium-90, Radium-223, Samarium-153, Strontium-89
ApplicationOncology, Cardiology, Neurology, Endocrinology, Gastroenterology, Nephrology, Orthopedics
End UserHospitals, Diagnostic Centers, Ambulatory Surgical Centers, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies
TechnologyCyclotron, Nuclear Reactor, Linear Accelerator
FormLiquid, Solid, Gaseous
ServicesRadioisotope Production, Radiopharmaceutical Manufacturing, Quality Control and Testing, Regulatory Compliance, Logistics and Distribution
ModeIn-house, Outsourced
StagePreclinical, Clinical, Commercial

Market Snapshot:

The radiopharmaceuticals market is characterized by dynamic market share distribution, competitive pricing strategies, and a surge in new product launches. Key players are focusing on innovative technologies to enhance their product portfolios. The market is witnessing a shift towards precision medicine, driving demand for targeted radiopharmaceutical therapies. North America remains a dominant player, with substantial investments in research and development. Europe and Asia-Pacific are also experiencing significant growth, propelled by increasing healthcare expenditure and technological advancements. Competition benchmarking reveals a landscape marked by strategic collaborations and mergers. Companies are leveraging partnerships to expand their global footprint and enhance product offerings. Regulatory influences play a pivotal role, with stringent guidelines impacting market entry and compliance. The U.S. FDA and the European Medicines Agency are key regulatory bodies shaping the market dynamics. As the market evolves, the focus on safety and efficacy continues to drive innovation, offering lucrative opportunities for stakeholders.

Geographical Overview:

The radiopharmaceuticals market is experiencing notable growth across various regions, each presenting unique opportunities. North America remains a dominant force, driven by advanced healthcare infrastructure and substantial investments in nuclear medicine. The region's focus on precision medicine and increasing prevalence of chronic diseases further bolster market expansion. Europe follows, with strong research and development initiatives and regulatory support enhancing market dynamics. The emphasis on innovative cancer therapies and diagnostics contributes to the region's growth. In Asia Pacific, the market is expanding rapidly, fueled by rising healthcare expenditures and increasing awareness of nuclear medicine's benefits. Emerging economies like China and India are pivotal in this growth trajectory. Latin America and the Middle East & Africa are emerging markets with significant potential. Latin America is witnessing increased adoption of radiopharmaceuticals, driven by improving healthcare infrastructure. Meanwhile, the Middle East & Africa are recognizing the importance of nuclear medicine in advancing healthcare outcomes, presenting lucrative opportunities for market players.

Key Trends and Drivers:

The radiopharmaceuticals market is experiencing robust growth driven by advancements in nuclear medicine and personalized healthcare. Key trends include the increasing use of radiopharmaceuticals in cancer diagnosis and treatment, where precision medicine is gaining prominence. The development of novel radiopharmaceuticals targeting specific cancer types is enhancing treatment efficacy and patient outcomes. Moreover, the rising prevalence of chronic diseases and an aging population are fueling demand for diagnostic imaging. Technological innovations, such as hybrid imaging systems, are further propelling market expansion. Regulatory support and favorable reimbursement policies are encouraging investment in radiopharmaceutical research and development. The market is also witnessing strategic collaborations between pharmaceutical companies and research institutions, fostering innovation. Opportunities abound in emerging markets, where healthcare infrastructure is improving. Companies that focus on expanding their product portfolio and geographic reach are well-positioned to capitalize on these trends. The radiopharmaceuticals market is poised for sustained growth, driven by ongoing scientific advancements and increasing healthcare demands.

Restraints and Challenges:

The radiopharmaceuticals market encounters several formidable restraints and challenges. One significant challenge is the stringent regulatory landscape. Regulatory bodies impose rigorous testing and approval processes, which can delay the introduction of new products. This creates a barrier to entry for smaller companies and stifles innovation. Another challenge is the high cost associated with radiopharmaceutical production. The need for specialized facilities and equipment increases operational expenses, limiting market expansion. Additionally, the short half-life of many radiopharmaceuticals necessitates a robust supply chain to ensure timely delivery, further complicating logistics. The market also faces a shortage of skilled professionals. Expertise in nuclear medicine is essential for the safe handling and application of radiopharmaceuticals, yet there is a limited pool of qualified personnel. Furthermore, public perception and fear of radiation pose hurdles. Misunderstandings about safety can lead to reluctance in adopting radiopharmaceutical treatments, affecting market growth.

Key Players:

Advanced Accelerator Applications, Blue Earth Diagnostics, ITM Isotope Technologies Munich, Lantheus Medical Imaging, Jubilant Radiopharma, Curium, Telix Pharmaceuticals, Bayer Radiopharma, NorthStar Medical Radioisotopes, Eckert & Ziegler, Sofie Biosciences, Cardinal Health Radiopharmacy, Isotopia Molecular Imaging, Radiomedix, ImaginAb

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Application
  • 2.4 Key Market Highlights by End User
  • 2.5 Key Market Highlights by Technology
  • 2.6 Key Market Highlights by Form
  • 2.7 Key Market Highlights by Services
  • 2.8 Key Market Highlights by Mode
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Diagnostic Radiopharmaceuticals
    • 4.1.2 Therapeutic Radiopharmaceuticals
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Technetium-99m
    • 4.2.2 Iodine-131
    • 4.2.3 Fluorodeoxyglucose (FDG)
    • 4.2.4 Gallium-68
    • 4.2.5 Lutetium-177
    • 4.2.6 Yttrium-90
    • 4.2.7 Radium-223
    • 4.2.8 Samarium-153
    • 4.2.9 Strontium-89
  • 4.3 Market Size & Forecast by Application (2020-2035)
    • 4.3.1 Oncology
    • 4.3.2 Cardiology
    • 4.3.3 Neurology
    • 4.3.4 Endocrinology
    • 4.3.5 Gastroenterology
    • 4.3.6 Nephrology
    • 4.3.7 Orthopedics
  • 4.4 Market Size & Forecast by End User (2020-2035)
    • 4.4.1 Hospitals
    • 4.4.2 Diagnostic Centers
    • 4.4.3 Ambulatory Surgical Centers
    • 4.4.4 Academic and Research Institutes
    • 4.4.5 Pharmaceutical and Biotechnology Companies
  • 4.5 Market Size & Forecast by Technology (2020-2035)
    • 4.5.1 Cyclotron
    • 4.5.2 Nuclear Reactor
    • 4.5.3 Linear Accelerator
  • 4.6 Market Size & Forecast by Form (2020-2035)
    • 4.6.1 Liquid
    • 4.6.2 Solid
    • 4.6.3 Gaseous
  • 4.7 Market Size & Forecast by Services (2020-2035)
    • 4.7.1 Radioisotope Production
    • 4.7.2 Radiopharmaceutical Manufacturing
    • 4.7.3 Quality Control and Testing
    • 4.7.4 Regulatory Compliance
    • 4.7.5 Logistics and Distribution
  • 4.8 Market Size & Forecast by Mode (2020-2035)
    • 4.8.1 In-house
    • 4.8.2 Outsourced
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Preclinical
    • 4.9.2 Clinical
    • 4.9.3 Commercial

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Application
      • 5.2.1.4 End User
      • 5.2.1.5 Technology
      • 5.2.1.6 Form
      • 5.2.1.7 Services
      • 5.2.1.8 Mode
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Application
      • 5.2.2.4 End User
      • 5.2.2.5 Technology
      • 5.2.2.6 Form
      • 5.2.2.7 Services
      • 5.2.2.8 Mode
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Application
      • 5.2.3.4 End User
      • 5.2.3.5 Technology
      • 5.2.3.6 Form
      • 5.2.3.7 Services
      • 5.2.3.8 Mode
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Application
      • 5.3.1.4 End User
      • 5.3.1.5 Technology
      • 5.3.1.6 Form
      • 5.3.1.7 Services
      • 5.3.1.8 Mode
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Application
      • 5.3.2.4 End User
      • 5.3.2.5 Technology
      • 5.3.2.6 Form
      • 5.3.2.7 Services
      • 5.3.2.8 Mode
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Application
      • 5.3.3.4 End User
      • 5.3.3.5 Technology
      • 5.3.3.6 Form
      • 5.3.3.7 Services
      • 5.3.3.8 Mode
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Application
      • 5.4.1.4 End User
      • 5.4.1.5 Technology
      • 5.4.1.6 Form
      • 5.4.1.7 Services
      • 5.4.1.8 Mode
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Application
      • 5.4.2.4 End User
      • 5.4.2.5 Technology
      • 5.4.2.6 Form
      • 5.4.2.7 Services
      • 5.4.2.8 Mode
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Application
      • 5.4.3.4 End User
      • 5.4.3.5 Technology
      • 5.4.3.6 Form
      • 5.4.3.7 Services
      • 5.4.3.8 Mode
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Application
      • 5.4.4.4 End User
      • 5.4.4.5 Technology
      • 5.4.4.6 Form
      • 5.4.4.7 Services
      • 5.4.4.8 Mode
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Application
      • 5.4.5.4 End User
      • 5.4.5.5 Technology
      • 5.4.5.6 Form
      • 5.4.5.7 Services
      • 5.4.5.8 Mode
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Application
      • 5.4.6.4 End User
      • 5.4.6.5 Technology
      • 5.4.6.6 Form
      • 5.4.6.7 Services
      • 5.4.6.8 Mode
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Application
      • 5.4.7.4 End User
      • 5.4.7.5 Technology
      • 5.4.7.6 Form
      • 5.4.7.7 Services
      • 5.4.7.8 Mode
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Application
      • 5.5.1.4 End User
      • 5.5.1.5 Technology
      • 5.5.1.6 Form
      • 5.5.1.7 Services
      • 5.5.1.8 Mode
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Application
      • 5.5.2.4 End User
      • 5.5.2.5 Technology
      • 5.5.2.6 Form
      • 5.5.2.7 Services
      • 5.5.2.8 Mode
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Application
      • 5.5.3.4 End User
      • 5.5.3.5 Technology
      • 5.5.3.6 Form
      • 5.5.3.7 Services
      • 5.5.3.8 Mode
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Application
      • 5.5.4.4 End User
      • 5.5.4.5 Technology
      • 5.5.4.6 Form
      • 5.5.4.7 Services
      • 5.5.4.8 Mode
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Application
      • 5.5.5.4 End User
      • 5.5.5.5 Technology
      • 5.5.5.6 Form
      • 5.5.5.7 Services
      • 5.5.5.8 Mode
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Application
      • 5.5.6.4 End User
      • 5.5.6.5 Technology
      • 5.5.6.6 Form
      • 5.5.6.7 Services
      • 5.5.6.8 Mode
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Application
      • 5.6.1.4 End User
      • 5.6.1.5 Technology
      • 5.6.1.6 Form
      • 5.6.1.7 Services
      • 5.6.1.8 Mode
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Application
      • 5.6.2.4 End User
      • 5.6.2.5 Technology
      • 5.6.2.6 Form
      • 5.6.2.7 Services
      • 5.6.2.8 Mode
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Application
      • 5.6.3.4 End User
      • 5.6.3.5 Technology
      • 5.6.3.6 Form
      • 5.6.3.7 Services
      • 5.6.3.8 Mode
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Application
      • 5.6.4.4 End User
      • 5.6.4.5 Technology
      • 5.6.4.6 Form
      • 5.6.4.7 Services
      • 5.6.4.8 Mode
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Application
      • 5.6.5.4 End User
      • 5.6.5.5 Technology
      • 5.6.5.6 Form
      • 5.6.5.7 Services
      • 5.6.5.8 Mode
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Advanced Accelerator Applications
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Blue Earth Diagnostics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 ITM Isotope Technologies Munich
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Lantheus Medical Imaging
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Jubilant Radiopharma
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Curium
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Telix Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Bayer Radiopharma
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 NorthStar Medical Radioisotopes
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Eckert & Ziegler
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Sofie Biosciences
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Cardinal Health Radiopharmacy
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Isotopia Molecular Imaging
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Radiomedix
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 ImaginAb
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us